MyFinsight
Home
Blog
About
Proceeds from exercise of
warrants
$9,730,285
Net proceeds from
loan agreement
$9,635,000
Net proceeds from
common stock offerings
$4,452,933
(-73.03%↓ Y/Y)
Net cash provided by
financing activities
$23,094,919
(31.90%↑ Y/Y)
Canceled cashflow
$1,723,299
Net change in cash
and cash...
$12,417,349
(337.66%↑ Y/Y)
Canceled cashflow
$10,677,570
Proceeds from (repayment
of) note payable and...
-$1,000,000
Deferred financing costs
$723,299
Stock-based compensation
expense
$3,810,665
(-52.05%↓ Y/Y)
Amortization of in-process
research and development
$1,720,312
Accounts receivable, net
of allowances
-$392,820
Prepaid expenses
-$345,222
(75.11%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
Amortization of operating
lease right-of-use...
$41,479
(-72.75%↓ Y/Y)
Inventory
-$33,645
(-100.38%↓ Y/Y)
Accrued expenses
$13,198
(-99.84%↓ Y/Y)
Net cash used in
operating activities
-$8,677,570
(40.86%↑ Y/Y)
Net cash used in
investing activities
-$2,000,000
Canceled cashflow
$6,536,833
Net loss
-$11,919,260
(61.55%↑ Y/Y)
License fee payments
$2,000,000
Accrued compensation
-$1,730,687
(-216.86%↓ Y/Y)
Accounts payable
-$1,415,904
(-127.40%↓ Y/Y)
Deferred income tax
expense (benefit)
-$107,347
(-113.54%↓ Y/Y)
Operating lease liability
-$41,205
(75.46%↑ Y/Y)
Back
Back
Cash Flow
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)
source: myfinsight.com